Core Viewpoint - The company is planning to increase its investment in Shanghai Huilun Pharmaceutical Co., Ltd. through a capital increase and share transfer, which is expected to enhance its competitiveness in the small molecule drug sector, particularly in the fields of oncology, cardiovascular, respiratory, and digestive system diseases [1][2]. Summary by Relevant Sections - **Investment Details** - The company will use its own funds of 40 million yuan for the investment, which includes 20 million yuan for acquiring 2,352,941 shares from Hubei Pinghu Venture Capital Co., Ltd. [1][2]. - **Transaction Classification** - The capital increase is classified as a related party transaction, while the share acquisition does not directly constitute a related party transaction but is subject to related transaction regulations [2]. - **Compliance and Fairness** - The agreements for the capital increase and share transfer are in compliance with relevant laws and regulations, ensuring that the pricing is fair and does not harm the interests of the company or its shareholders, particularly minority shareholders [2][3].

贵阳新天药业股份有限公司 第八届董事会第一次独立董事专门会议审核意见 贵阳新天药业股份有限公司（以下简称"公司"）第八届董事会第一次独立 董事专门会议于 2025 年 8 月 18 日以通讯会议的方式召开，会议应到独立董事 3 名，实际出席会议并表决的独立董事 3 名。会议的召开符合《公司法》《上市公 司独立董事管理办法》等法律法规、规范性文件和《公司章程》的有关规定。 经与会独立董事审议，本次会议通过了拟提交公司第八届董事会第二次会议 审议的《关于对参股公司增资并受让其部分股权暨关联交易的议案》，并发表审 核意见如下： 三、公司拟与交易对方签署的《增资协议》、《股份转让协议》符合相关法律、 法规、规范性文件的规定及监管规则的要求。 四、本次公司对汇伦医药增资及受让苹湖创投持有的汇伦医药股份的定价均 是结合标的公司实际情况协商一致的结果，遵循客观公正、平等自愿、价格公允 的市场定价原则，符合有关法律法规的规定，不存在有失公允或损害公司利益的 情形。 综上所述，公司本次交易符合国家有关法律、法规和规范性文件的规定，不 存在损害公司及全体股东特别是中小股东利益的情形，我们同意《关于对参股公 司增资并受让其部分股权 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-051 贵阳新天药业股份有限公司 关于对参股公司增资并受让其部分股权 暨关联交易的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 本次交易完成后，公司对汇伦医药的累计投资额为 36,000.00 万元人民币， 公司持有汇伦医药股份的比例将由 14.5971%（汇伦医药前期融资导致公司持股 比例从 15.3748%降至 14.5971%）增加至 15.4567%。 本次交易属于关联交易（或适用关联交易的程序），不构成重大资产重组， 相关交易的实施不存在法律障碍。本次交易属于公司董事会决策权限范围，无需 提交公司股东会审议。 一、交易概述 1 （一）交易基本情况 根据公司中长期发展战略目标，为进一步加大公司在小分子化学药等前沿医 药领域的产业布局，加速打造行业领先的综合性医药企业，公司于 2025 年 8 月 21 日召开第八届董事会第二次会议，审议通过了《关于对参股公司增资并受让 其部分股权暨关联交易的议案》，同意公司使用自有资金 4,000 万元以"增资+ 受让"方式，增加对关联方汇伦医药的 ...

| 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 机构专用 | 3650.47 | 1213.19 | | 买二 | 机构专用 | 2414.13 | 925.14 | | 买三 | 中国国际金融股份有限公司上海分公司 | 2102.60 | 90.18 | | 买四 | 华泰证券股份有限公司上海浦东新区世纪大道证券营业 | 1203.06 | 49.05 | | | 部 | | | | 买五 | 机构专用 | 1155.49 | 1205.40 | | 卖一 | 开源证券股份有限公司西安西大街证券营业部 | 4.81 | 2274.04 | | 卖二 | 机构专用 | 1089.95 | 2114.89 | | 卖三 | 机构专用 | 787.07 | 1290.27 | | 卖四 | 机构专用 | 3650.47 | 1213.19 | | 卖五 | 机构专用 | 1155.49 | 1205.40 | 证券时报·数据宝统计显示，上榜的前五大买卖营业部合计成交2.16亿元，其中，买入成 ...

（文章来源：证券日报） 证券日报网讯新天药业8月19日在互动平台回答投资者提问时表示，截至2025年8月8日，公司股东人数 为32817户。 ...

证券之星消息，8月19日中药板块较上一交易日上涨0.57%，ST香雪领涨。当日上证指数报收于3727.29， 下跌0.02%。深证成指报收于11821.63，下跌0.12%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300147 | ST香雪 | 10.54 | 20.05% | 66.89万 | | 6.52亿 | | 600594 | 益僧制药 | 4.59 | 10.07% | 42.52万 | | 1.89亿 | | 603139 | 康惠制药 | 25.18 | 10.00% | 3.83万 | | 9369.95万 | | 002873 | 新天药业 | 15.19 | 9.99% | 1 29.29万 | | 4.38亿 | | 600557 | 康家药业 | 19.83 | 9.98% | 39.16万 | | 7.74亿 | | 600671 | 天目药业 | 16.89 | 6.03% | 9.59万 | | 1.58亿 | | ...

新天药业盘中涨停，已连收3个涨停板，截至9:43，该股报15.19元，换手率10.71%，成交量2556.67万 股，成交金额3.81亿元，涨停板封单金额为2.74亿元。连续涨停期间，该股累计上涨33.13%，累计换手 率为50.37%。最新A股总市值达37.08亿元，A股流通市值36.25亿元。 龙虎榜数据显示，该股因连续三个交易日内，涨幅偏离值累计达20%上榜龙虎榜1次，买卖居前营业部 中，机构净卖出895.28万元，营业部席位合计净买入2050.92万元。 7月31日公司发布的半年报数据显示，上半年公司共实现营业总收入3.58亿元，同比下降18.89%，实现 净利润576.61万元，同比下降81.00%。（数据宝） 近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.08.18 | 10.04 | 21.73 | 12756.46 | | 2025.08.15 | 9.99 | 17.92 | 9895.06 | | 2025.08.14 | 1.15 | 14.31 | 1637.00 | | ...

Group 1 - The A-share market saw a significant rise in pharmaceutical stocks, with notable performances including Furuide Co., Ltd. hitting a 20% limit up, and Boji Pharmaceutical rising by 14% [1] - Other companies such as Jimin Health and Kangyuan Pharmaceutical also experienced substantial gains, with both reaching a 10% limit up [1] - The overall trend indicates a bullish sentiment in the pharmaceutical sector, with multiple stocks showing increases of over 5% [1] Group 2 - Furuide Co., Ltd. reported a market capitalization of 19.1 billion and a year-to-date increase of 129.01% [2] - Boji Pharmaceutical had a market cap of 4.819 billion and a year-to-date increase of 43.33% [2] - Other notable companies include Jimin Health with a market cap of 5.66 billion and a year-to-date increase of 58.76%, and Kangyuan Pharmaceutical with a market cap of 11.2 billion and a year-to-date increase of 45.59% [2]

Market Overview - The A-share market continued to rebound, with the Shanghai Composite Index rising by 0.44%, the Shenzhen Component Index by 0.57%, and the ChiNext Index by 1.04% as of 9:45 AM on August 19 [1] - The pharmaceutical sector showed strong performance, particularly in innovative drugs, with Ji Min Health hitting the daily limit [1] - AI hardware stocks like New Yisheng and Zhongji Xuchuang reached historical highs, while sectors such as film, media, military, banking, oil and gas, and wind power experienced declines [1] Key Sectors Innovative Drug Sector - The innovative drug sector saw significant gains, with Ji Min Health and Kangyuan Pharmaceutical hitting the daily limit, and other companies like Nuo Si Lan De and Li Fang Pharmaceutical also rising [2] - CITIC Securities reports a favorable policy environment for innovative drugs starting from 2025, recommending investments in innovation-driven and internationalization strategies, particularly in the innovative drug field [2] CPO Concept - CPO concept stocks maintained strong performance, with New Yisheng and Zhongji Xuchuang reaching historical highs, and companies like Jianqiao Technology and Tengjing Technology also seeing gains [3] - CITIC Jiantou Securities highlights a shift in AI training network architecture, leading to increased demand for optical modules, with 800G optical modules expected to see significant growth starting in 2023 [3] Institutional Insights Shenwan Hongyuan - Shenwan Hongyuan believes the short-term bull market atmosphere will continue to dominate, with a focus on securities, insurance, military, and rare earth sectors before early September [4] - The firm emphasizes the importance of sectors with scarce overseas computing power and suggests a price alliance in high market share manufacturing segments [4] Huatai Securities - Huatai Securities suggests that the market may have entered the mid-stage of a bull market, characterized by structural features and rapid sector rotation [5] - The firm notes that the current slow bull market may extend the upward cycle, with a need for increased market signals to attract more external funds [5] Dongfang Securities - Dongfang Securities anticipates no major adjustment risks for stock indices in August, with a "local advance, multi-point bloom" characteristic in the current market [6] - The firm advises caution against potential pullbacks and emphasizes the importance of "high-low switching" in the event of market adjustments, recommending focus on technology autonomy, innovative drugs, military, and robotics sectors [6]

Group 1 - The company clarified that recent rumors regarding its entry into the supply chains of Nvidia, Meta, Google, Huawei, and Cambricon are false, stating that no contracts have been signed with these companies [2][5][6] - Since August 11, the company's stock has experienced significant volatility, with five out of six trading days hitting the daily limit, resulting in an approximate 70% increase in stock price, reaching a multi-year high [2][6] - The company operates in two main business segments: energy and set-top boxes, with key products including 18650 lithium batteries, various polymer soft-pack batteries, digital TV set-top boxes, smart terminals, and comprehensive digital TV solutions [4] Group 2 - The company's half-year report indicated substantial growth in revenue and profit for the first half of 2025, driven by the ongoing production and sales of high-power power supply products [6] - Other companies, such as Yingweike and Huasheng Tiancai, have also issued announcements to clarify market rumors, with Yingweike's stock rising over 110% since the end of July [7][12] - Huasheng Tiancai's stock has seen a cumulative increase of 106.8% since July 18, 2025, although the company noted that its stock price has diverged significantly from its fundamental performance [14]